Hospital
Doctors Medical Center of Modesto, INC.
Doctors Medical Center of Modesto, INC. was paid $101.26M by Medicaid between Jan 2018 and Dec 2024, across 282 billing codes. Its largest line is 0450, Emergency room services — 37% of everything it billed.
33Billing provider infoDOCTORS MEDICAL CENTER OF MODESTO, INC.
MODESTO, CA 95350
MODESTO, CA 95350
33aNPI1184654923assigned 07/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$101.26M
24GClaims1,373,383
24DCodes billed282
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#20 of 410
Median peer was paid$6.90M
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 312,924 | $17.19M | |
| 2019 | 228,296 | $16.76M | |
| 2020 | 165,401 | $14.58M | |
| 2021 | 167,232 | $12.70M | |
| 2022 | 171,947 | $14.78M | |
| 2023 | 180,157 | $13.82M | |
| 2024incomplete | 147,426 | $11.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 37% | 206,773 | 178,950 | $37.38M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.3% | 42,563 | 39,043 | $7.42M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.7% | 34,749 | 31,912 | $3.74M |
| 99218 | 3.1% | 2,238 | 1,160 | $3.12M | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.1% | 8,776 | 8,632 | $3.10M |
| 71046 | Radiologic examination, chest; 2 views | 2.7% | 21,939 | 21,134 | $2.70M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.6% | 15,728 | 14,347 | $2.67M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 7,084 | 6,780 | $2.53M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 10,074 | 9,457 | $2.52M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.4% | 4,117 | 4,011 | $2.39M |
| 0762 | 1.9% | 2,136 | 1,235 | $1.97M | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 10,552 | 10,104 | $1.84M |
270 more codes
| 71045 | Radiologic examination, chest; single view | 1.8% | 19,121 | $1.78M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 26,890 | $1.73M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 21,089 | $1.48M |
| Z7502 | 1.1% | 30,705 | $1.15M | |
| 80053 | Comprehensive metabolic panel | 1.0% | 70,310 | $1.05M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 16,767 | $899K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,419 | $897K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,432 | $790K |
| 0270 | <1% | 17,787 | $789K | |
| 93458 | <1% | 401 | $707K | |
| 93017 | <1% | 5,349 | $645K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 85,949 | $634K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 8,216 | $630K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 41,805 | $625K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,251 | $606K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,387 | $533K |
| 0510 | <1% | 18,743 | $492K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,630 | $469K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 3,594 | $454K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,114 | $450K |
| J3490 | Unclassified drugs | <1% | 14,562 | $421K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 2,555 | $405K |
| 76801 | <1% | 2,620 | $390K | |
| 0360 | <1% | 2,854 | $387K | |
| Z9725 | <1% | 8,427 | $363K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,713 | $361K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 7,925 | $357K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,339 | $336K |
| 93880 | <1% | 2,217 | $331K | |
| 73610 | <1% | 2,745 | $304K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,095 | $273K |
| 73630 | <1% | 2,843 | $245K | |
| 0760 | <1% | 7,447 | $232K | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 155 | $229K |
| 0121 | <1% | 50 | $229K | |
| 73562 | <1% | 2,384 | $226K | |
| 74018 | <1% | 2,181 | $214K | |
| 73030 | <1% | 2,323 | $210K | |
| 73130 | <1% | 2,169 | $204K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 7,918 | $201K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,088 | $192K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,315 | $184K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 25,738 | $167K |
| 87632 | <1% | 1,235 | $146K | |
| 73110 | <1% | 1,399 | $132K | |
| 84484 | <1% | 17,850 | $130K | |
| 70486 | <1% | 767 | $128K | |
| 93296 | <1% | 8,367 | $126K | |
| 85610 | <1% | 16,695 | $125K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,825 | $121K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,521 | $120K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 16,172 | $116K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,063 | $114K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 127 | $111K |
| 0272 | <1% | 4,664 | $102K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 315 | $99K |
| 83690 | <1% | 18,794 | $95K | |
| 72100 | <1% | 916 | $95K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 3,975 | $92K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,203 | $92K |
| 93971 | <1% | 1,304 | $90K | |
| 81025 | <1% | 20,335 | $89K | |
| 83880 | <1% | 6,060 | $88K | |
| 94060 | <1% | 683 | $88K | |
| 73080 | <1% | 757 | $86K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,884 | $85K |
| 76830 | Ultrasound, transvaginal | <1% | 600 | $83K |
| 74022 | <1% | 492 | $82K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 427 | $81K |
| 86850 | <1% | 4,252 | $79K | |
| Q3014 | Telehealth originating site facility fee | <1% | 4,240 | $79K |
| 73590 | <1% | 892 | $77K | |
| 0250 | <1% | 27,448 | $76K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,050 | $76K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,046 | $75K |
| 81003 | <1% | 28,280 | $74K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,756 | $73K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,155 | $73K |
| 72131 | <1% | 341 | $73K | |
| 36600 | <1% | 394 | $72K | |
| 85730 | <1% | 5,207 | $71K | |
| 73502 | <1% | 621 | $71K | |
| 72040 | <1% | 461 | $68K | |
| 12001 | <1% | 355 | $65K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,044 | $65K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,875 | $62K |
| 76818 | <1% | 310 | $61K | |
| 90715 | <1% | 1,816 | $60K | |
| 87081 | <1% | 3,135 | $59K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,237 | $57K |
| 76870 | <1% | 395 | $56K | |
| 0682 | <1% | 41 | $54K | |
| 0761 | <1% | 1,424 | $52K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,887 | $50K |
| 73090 | <1% | 582 | $47K | |
| 84702 | <1% | 5,260 | $47K | |
| 86901 | <1% | 6,216 | $46K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,658 | $46K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,457 | $45K |
| 86900 | <1% | 6,216 | $45K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,681 | $45K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,126 | $44K |
| 12002 | <1% | 233 | $43K | |
| 10060 | <1% | 210 | $42K | |
| 73140 | <1% | 337 | $42K | |
| 0710 | <1% | 2,672 | $42K | |
| 0160 | <1% | 807 | $41K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,435 | $40K |
| 86140 | <1% | 10,030 | $39K | |
| 99199 | Unlisted special service, procedure or report | <1% | 756 | $38K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,450 | $38K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,896 | $37K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,002 | $37K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 277 | $37K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,240 | $35K |
| 29515 | <1% | 185 | $35K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,779 | $34K |
| 87040 | <1% | 3,788 | $34K | |
| 85027 | <1% | 4,890 | $34K | |
| 12011 | <1% | 172 | $33K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 269 | $33K |
| 74019 | <1% | 250 | $32K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 226 | $31K |
| 87186 | <1% | 4,076 | $30K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 830 | $30K |
| 94664 | <1% | 3,435 | $29K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,884 | $29K |
| 99205 | Prolong outpt/office vis | <1% | 614 | $28K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,404 | $27K |
| 81001 | <1% | 15,126 | $27K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,569 | $26K |
| 80047 | <1% | 2,013 | $26K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,496 | $26K |
| 82550 | <1% | 6,819 | $25K | |
| 94726 | <1% | 261 | $25K | |
| 96376 | <1% | 323 | $24K | |
| 59025 | Fetal non-stress test | <1% | 1,003 | $24K |
| 82247 | <1% | 1,653 | $23K | |
| 82962 | <1% | 8,971 | $22K | |
| 82553 | <1% | 4,674 | $22K | |
| 83605 | <1% | 2,533 | $22K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,640 | $21K |
| 83735 | <1% | 4,321 | $21K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 683 | $19K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 2,277 | $19K |
| 94729 | <1% | 261 | $19K | |
| 87077 | <1% | 4,077 | $18K | |
| 93299 | <1% | 929 | $18K | |
| 93970 | <1% | 123 | $17K | |
| 71020 | <1% | 596 | $16K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 922 | $16K |
| 0300 | <1% | 855 | $15K | |
| 72128 | <1% | 29 | $15K | |
| 0320 | <1% | 393 | $14K | |
| 82248 | <1% | 1,062 | $14K | |
| 93226 | <1% | 379 | $13K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 60 | $12K |
| 73560 | <1% | 100 | $11K | |
| Z7610 | <1% | 868 | $11K | |
| 0271 | <1% | 2,179 | $11K | |
| 84145 | <1% | 743 | $11K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,391 | $11K |
| 76770 | <1% | 62 | $11K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,720 | $10K |
| 93225 | <1% | 412 | $10K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 89 | $10K |
| 70360 | <1% | 61 | $8K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 53 | $8K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,741 | $8K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 275 | $8K |
| 29130 | <1% | 31 | $7K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 193 | $7K |
| 73564 | <1% | 41 | $7K | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 534 | $7K |
| 70491 | <1% | 30 | $6K | |
| 73552 | <1% | 59 | $6K | |
| 85379 | <1% | 965 | $6K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 550 | $6K |
| 84439 | <1% | 731 | $6K | |
| 0255 | <1% | 74 | $6K | |
| 85652 | <1% | 2,805 | $6K | |
| 73660 | <1% | 40 | $6K | |
| 81002 | <1% | 2,817 | $5K | |
| 80061 | Lipid panel | <1% | 647 | $5K |
| 86780 | <1% | 625 | $5K | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 17 | $5K |
| 0002A | <1% | 132 | $5K | |
| 94644 | <1% | 528 | $5K | |
| 0001A | <1% | 136 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 364 | $5K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 674 | $4K |
| 29105 | <1% | 25 | $4K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $4K |
| 71010 | <1% | 236 | $4K | |
| 72072 | <1% | 37 | $4K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 27 | $4K |
| 71101 | <1% | 25 | $3K | |
| 82731 | <1% | 235 | $3K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 274 | $3K |
| 0370 | <1% | 824 | $3K | |
| 70496 | <1% | 15 | $3K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 84 | $3K |
| 96367 | <1% | 118 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 180 | $3K |
| 93925 | <1% | 26 | $3K | |
| 72170 | <1% | 71 | $3K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 12 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 428 | $2K |
| 73060 | <1% | 37 | $2K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $2K |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 90 | $2K |
| 70498 | <1% | 15 | $2K | |
| 82140 | <1% | 274 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 150 | $2K |
| 84550 | <1% | 686 | $2K | |
| 83518 | <1% | 315 | $2K | |
| 85384 | <1% | 327 | $2K | |
| Z7500 | <1% | 51 | $2K | |
| 86923 | <1% | 16 | $2K | |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 40 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 119 | $1K |
| 74000 | <1% | 41 | $1K | |
| 86403 | <1% | 200 | $1K | |
| 87070 | <1% | 279 | $1K | |
| 99070 | <1% | 47 | $1K | |
| 87210 | <1% | 581 | $1K | |
| 85362 | <1% | 180 | $1K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 50 | $1K |
| A4217 | Sterile water/saline, 500 ml | <1% | 157 | $970.85 |
| 86703 | <1% | 188 | $881.69 | |
| 97161 | <1% | 44 | $845.81 | |
| 29125 | <1% | 130 | $797.86 | |
| 81015 | <1% | 141 | $793.86 | |
| 94760 | <1% | 226 | $777.90 | |
| 84100 | <1% | 308 | $709.63 | |
| 82570 | <1% | 180 | $641.87 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 350 | $640.04 |
| 0031A | <1% | 15 | $600.00 | |
| 86592 | <1% | 348 | $591.84 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 31 | $562.77 |
| 87486 | <1% | 28 | $548.69 | |
| 87581 | <1% | 28 | $548.69 | |
| 87506 | <1% | 13 | $511.20 | |
| 93922 | <1% | 13 | $467.52 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 68 | $446.54 |
| 80076 | <1% | 124 | $435.79 | |
| A9270 | Non-covered item or service | <1% | 303 | $423.13 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 14 | $414.84 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 51 | $382.23 |
| 83615 | <1% | 36 | $374.89 | |
| 84156 | <1% | 150 | $328.79 | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $315.00 |
| 82728 | <1% | 24 | $297.11 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 34 | $215.80 |
| 94010 | <1% | 12 | $204.30 | |
| 87147 | <1% | 82 | $171.67 | |
| 84132 | <1% | 16 | $153.64 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 20 | $152.37 |
| 29505 | <1% | 37 | $129.67 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 13 | $110.27 |
| 0258 | <1% | 139 | $106.40 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 16 | $76.88 |
| 86308 | <1% | 28 | $67.48 | |
| 62370 | <1% | 14 | $58.00 | |
| 0420 | 0% | 79 | $0.00 | |
| 0350 | 0% | 96 | $0.00 | |
| 99441 | 0% | 29 | $0.00 | |
| 0440 | 0% | 12 | $0.00 | |
| 0730 | 0% | 100 | $0.00 | |
| 0430 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGARDNER, BRANDON (CFO)